Clinical trial NCT03069248: Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon
Official title: Treatment of Follicular Non-Hodgkin's Lymphoma With High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy With Rituximab and Alpha Interferon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Follicular Lymphoma
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
First posted: 2017-03-03
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a non-comparative, prospective, non-randomized single centre phase II clinical trial of Rituximab and alpha interferon immunotherapy following autologous stem cell transplant in patients with relapsed follicular lymphoma conducted at Toronto Sunnybrook Regional Cancer Centre/Sunnybrook and Women's Health Sciences Centre.


Eligibility criteria: Inclusion Criteria:

* Patients with 1-2 relapses of WHO Classification follicle centre NHL grade 1-2/3. Patients must have achieved at least a PR to previous treatment.
* Central pathology review before registration
* Ann Arbor stage III or IV
* Measurable disease: defined as clinically or radiologically documented disease with at least one site bidimensionally measurable using clinical exam, CT or MRI performed in the 3 weeks prior to study enrollment.
* ECOG performance status of \<2.
* Patients may have received not more than 1 prior course (4 infusions) of rituximab. Timing of rituximab must exceed 12 months prior to registration. Patients must have demonstrated at least a PR to rituximab if previously administered.
* Patient consent according to institutional and university human experimentation committee requirements
* Adequate Renal, hepatic and hematopoietic function test unless the abnormal values are thought to be due to involvement with lymphoma as defined by:

Hb\> 85 ANC \>1000/mm3 Platelets \>100,000/mm3 Serum/Total Bilirubin \>=2 SI units AST/ALT \<2x Upper Limit of Normal

Exclusion Criteria:

* Positive serology for HIV
* Uncontrolled Infection
* Pregnancy
* CNS Metastases
* History of Psychiatric Disorder
* Other Malignancy (except nonmelanoma skin cancer)
* Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions, which, in the opinion of the investigator and/or the sponsor, would compromise other protocol objectives.
* Major surgery, other than diagnostic surgery, within four weeks.
* Presence of anti-murine antibody (HAMA) reactivity. These laboratory results must be available prior to receiving treatment for those patients
* who have received prior murine proteins or patients who have allergies to murine proteins.
* New York Heart Association Class III or IV heart disease (see Appendix H, Clinical Evaluation of Functional Capacity of Patients with Heart Disease in Relation to Ordinary Physical Activity) or myocardial infarction within the past six months.
* Treatment with an investigational drug within 30 days or five half-lives (of the study drug with the longest half-life) prior to entry into the study, which ever is longer.
* Previous chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix within the last 5 years.
* History of allergic reactions to compounds chemically related to Rituximab.
* Refusal to practice contraception if of reproductive potential.

Primary outcomes:
measure: Survival (Overall survival)
timeFrame: From date of randomization until date of death or last follow-up, whichever comes first, assessed up to 116 months
measure: Survival (Progression free survival)
timeFrame: From date of randomization until date of relapse or disease progression, assessed up to 116 months
Secondary outcomes:
measure: Toxicities (Possible transplant-related adverse events)
timeFrame: assessed semi-annually, from date of enrollment up to 116 months
measure: Minimal Residual Disease
timeFrame: assessed semi-annually, from date of enrollment up to 116 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Sunnybrook Health Sciences Centre, Odette Cancer Centre
state: Ontario
Study officials:
affiliation: Sunnybrook Health Sciences Centre
name: Neil Berinstein, MD
role: PRINCIPAL_INVESTIGATOR
References: